New Company to Treat Substance Use Disorders, Anxiety
UK biotech investment firm Aditum Bio and Japan-based Sosei Heptares have created a new company, Tempero Bio, to develop therapies for the treatment of substance use disorders and anxiety.
Tempero Bio will develop treatments based on Sosei’s investigational oral drug HTL0014242, now renamed TMP-301 and which is currently in early-stage studies.
Under the agreement, Sosei will receive an upfront payment and equity in the new company and will be eligible for future milestone payments and royalties. Financial terms of the transaction were not disclosed.